These findings are congruent with the studies that showed a mechanistic link between elevated FGF-2 levels and visceral adiposity, inflammation, and tumorigenesis and between decreased FGF-2 levels and protection against visceral adiposity, inflammation and hepatic steatosis [[70], [71], [72]]. The gene discussed is FGF2; the disease is Hepatic steatosis.